Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 1/20 | 0.46 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29174383 | 0.84 | CYP1B1 (0.62) | ALDH1A1POLBGAASMN1; SMN2NPSR1 | |
| SCHEMBL6357561 | 0.82 | DRD3 (0.51) | CA12CA9DRD3ALDH1A1POLB | |
| SCHEMBL4578025 | 0.80 | ALDH1A1 (0.47) | CA12CA9DRD3ALDH1A1POLB | |
| SCHEMBL20931184 | 0.80 | ALDH1A1 (0.47) | CA12CA9DRD3ALDH1A1POLB | |
| SCHEMBL23124181 | 0.79 | ALDH1A1 (0.47) | CA12CA9DRD3ALDH1A1POLB | |
| SCHEMBL1862779 | 0.78 | ALDH1A1 (0.49) | CA12CA9DRD3ALDH1A1POLB | |
| SCHEMBL10851246 | 0.78 | ALDH1A1 (0.52) | CA12CA9DRD3ALDH1A1POLB | |
| SCHEMBL4632890 | 0.78 | ALDH1A1 (0.49) | CA12CA9DRD3ALDH1A1POLB | |
| SCHEMBL9698514 | 0.78 | ALDH1A1 (0.49) | CA12CA9DRD3ALDH1A1POLB | |
| SCHEMBL6898278 | 0.78 | CHRM2 (0.53) | SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116283799-A | Quinazoline methionine adenosyltransferase 2A inhibitors | 南京正大天晴制药有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-10486148-B2 | Ni(0) catalysts | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-11-26 | — | — | US | disclosed |
| US-20180264448-A1 | NI(0) CATALYSTS | NATIONAL SCIENCE FOUNDATION | 2018-09-20 | — | — | US | disclosed |
| US-9464033-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9452153-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160193181-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-07-07 | — | — | US | disclosed |
| US-9212187-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150329473-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2015-11-19 | — | — | US | disclosed |
| US-9115056-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9056849-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-5440048-A | Treating psychoses | HOECHST-ROUSSEL PHARMACEUTICALS INC (US) | 1995-08-08 | — | — | US | disclosed |
| EP-0661979-A1 | CROSS-LINKING OLIGONUCLEOTIDES FOR ENZYME-MEDIATED TRIPLE STRAND FORMATION | MICROPROBE CORPORATION (US) | 1995-07-12 | — | — | EP | disclosed |
| WO-1994017092-A1 | BIFUNCTIONAL CROSSLINKING OLIGONUCLEOTIDES ADAPTED FOR LINKING TO A DESIRED GENE SEQUENCE OF INVADING ORGANISM OR CELL | MICROPROBE CORPORATION (US) | 1994-08-04 | — | — | WO | disclosed |
| US-5334715-A | For treating psychological disorders | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1994-08-02 | — | — | US | disclosed |
| US-5194436-A | For trating psychosis | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1993-03-16 | — | — | US | disclosed |
| EP-0472648-A4 | CROSSLINKING OLIGONUCLEOTIDES | — | 1992-09-16 | — | — | EP | disclosed |
| EP-0494604-A1 | 1-Piperazinyl-2-butenes and 2-butynes, intermediates thereof, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-07-15 | — | — | EP | disclosed |
| US-5130315-A | Treatment of psychosis | Wittekind, Raymond R. (US) | 1992-07-14 | — | — | US | disclosed |
| EP-0472648-A1 | CROSSLINKING OLIGONUCLEOTIDES | MICROPROBE CORPORATION (US) | 1992-03-04 | — | — | EP | disclosed |
| WO-1990014353-A1 | CROSSLINKING OLIGONUCLEOTIDES | MICROPROBE CORPORATION (US) | 1990-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193181-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | CA12 4153/4885CA9 3040/4885DRD3 69/4885 |
| US-20150329473-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, STARD3, PDE6C | CA12 4660/4885CA9 2887/4885DRD3 924/4885 |
| US-10486148-B2 | Ni(0) catalysts | SOD1, SCO2, CNOT9 | CA12 280/4885CA9 143/4885DRD3 2474/4885 |
| US-20180264448-A1 | NI(0) CATALYSTS | SOD1, SCO2, CNOT9 | CA12 280/4885CA9 143/4885DRD3 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.